An interventional study of Patient nudge and Provider nudge in Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine. Completed at 1 site in United States. Open to female participants aged 40 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Abramson Cancer Center at Penn Medicine · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine — 11 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Abramson Cancer Center at Penn Medicine.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, this one is the 6th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, and was the 59th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →11 of the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine are open now, in 1 country. Recruiting first, the newest first:
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+
Abramson Cancer Center at Penn Medicine · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 40 Years to 74 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 11
First in 1998; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,358 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 53 across the 45 interventional studies, 110 across the 22 observational. Of the 44 that completed or were terminated, 8 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
Abramson Cancer Center at Penn Medicine is the lead sponsor of 462 studies on the registry; 88 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 14 (42%) have results posted.
5 of the studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06332131Abramson Cancer Center at Penn MedicineEffects of Immune Checkpoint Inhibitors on Coronary Microvasculature | 2026-11 |
| NCT03863457Abramson Cancer Center at Penn Medicine[18F] F-GLN by PET/CT in Breast Cancer | 2026-12 |
| NCT04841148Abramson Cancer Center at Penn MedicineAvelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer | 2027-07 |
| NCT03083288Abramson Cancer Center at Penn MedicineEvaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer | 2027-07 |
| NCT04855552Abramson Cancer Center at Penn MedicineTelehealth Weight Loss Program for Breast Cancer Survivors | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 68 studies in Breast Neoplasms by Abramson Cancer Center at Penn Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to increase MRI utilization among women with extremely dense breasts. The main question it seeks to answer is whether nudging of the provider, patient, or both increases the uptake of MRI among this group, and whether this effect differs between Black and White women.
Women with dense breasts have 3-5-fold increased risk for breast cancer as women without dense breasts. Dense breast tissue can "mask" small tumors, leading to reduced mammography sensitivity. Recent randomized controlled trials demonstrate that supplemental breast MRI screening improves detection of small, invasive cancers that are not detected by mammography. In January 2022, a Pennsylvania law went into effect mandating insurance coverage of supplemental screening for women with extremely dense breasts. Currently only a small fraction of eligible women with extremely dense breasts are receiving supplemental breast MRI screening. Clinical pathways to identify patients who are eligible for insurance coverage of supplemental breast MRI screening and communicate this option to patients and providers are needed to ensure equitable access to supplemental screening. This study therefore proposes a stepped wedge cluster randomized clinical trial to determine whether electronic health record (EHR) and secure text message nudges increase utilization of supplemental breast MRI screening among eligible women with extremely dense breasts.
Patient participants:
Inclusion Criteria:
Exclusion Criteria:
Provider participants:
Inclusion Criteria:
Usual standard of care, no nudging.
Nudge sent to provider through electronic health record (EHR).
Behavioral: Provider nudge
Nudge sent to the patient through text messaging.
Behavioral: Patient nudge
Nudge sent to both provider through EHR, and to patient through text messaging.
Behavioral: Patient nudge · Behavioral: Provider nudge
Nudge directed to the patient with the aim of increasing the uptake of MRI in patients with extremely dense breasts
Nudge directed to the provider with the aim of increasing ordering of MRI in patients with extremely dense breasts
Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled
Whether a breast MRI is ordered and/or scheduled within 6 months of the mammogram date
Time frame: 6 months
Number of Patients for Whom Breast MRI Was Ordered
Whether an MRI is ordered within 6 months of the mammogram date. Analyzed separately from scheduling.
Time frame: 6 months
Number of Patients Who Scheduled a Breast MRI
Whether an MRI is scheduled within 6 months of the mammogram date. Analyzed separately from ordering.
Time frame: 6 months
Number of Patients Who Completed a Breast MRI
Whether an MRI is completed within 6 months of the mammogram date
Time frame: 6 months
False-positive Rate
False-positive rate among those women who schedule and undergo MRI, defined as the number of patients who received a positive MRI result (i.e., BIRADS score of 4 or 5) but did not have a subsequent cancer diagnosis
Time frame: 6 months
Cancer Detection Rate
Cancer detection rate among those women who schedule and undergo MRI
Time frame: 6 months
A total of 292 clinicians from 33 clinics ordered mammograms for patients accruing to the trial. Clinicians were grouped into 10 clinic groups based on where they saw accrued patients. They were not enrolled themselves or consented; EHR changes were considered standard of practice. Part of the randomization (i.e., clinician nudge activation) occurred at the clinic group level, and another (i.e., independent patient randomization and patient nudge implementation) occurred at the patient level.
| Milestone | Step 1: Usual Care (1 Month), Patient Nudge Only (1 Month) | Step 2: Usual Care, Patient Nudge (2 Months) | Step 3: Usual Care, Patient Nudge (3 Months); Provider Nudge Only, Patient+Provider Nudge (1 Month) | Step 4: Usual Care, Patient Nudge (4 Months); Provider Nudge Only, Patient+Provider Nudge (2 Months) | Step 5: Usual Care, Patient Nudge (5 Months); Provider Nudge Only, Patient+Provider Nudge (3 Months) | Step 6: Usual Care, Patient Nudge (6 Months); Provider Nudge Only, Patient+Provider Nudge (4 Months) | Step 7: Usual Care, Patient Nudge (7 Months); Provider Nudge Only, Patient+Provider Nudge (5 Months) | Step 8: Usual Care, Patient Nudge (8 Months); Provider Nudge Only, Patient+Provider Nudge (6 Months) | Step 9: Usual Care, Patient Nudge (9 Months); Provider Nudge Only, Patient+Provider Nudge (7 Months) | Step 10: Usual Care, Patient Nudge (10 Months); Provider Nudge Only, Patient + Provider (8 Months) | Step 11: Usual Care, Patient Nudge (11 Months); Provider Nudge Only, Patient + Provider (9 Months) | Step 12: Usual Care (12 Months); Provider Nudge Only, Patient + Provider Nudge (10 Months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 61 | 123 | 115 | 108 | 97 | 130 | 136 | 105 | 128 | 97 | 94 | 164 |
| Completed | 61 | 123 | 115 | 108 | 97 | 130 | 136 | 105 | 128 | 97 | 94 | 164 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Whether a breast MRI is ordered and/or scheduled within 6 months of the mammogram date
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| Number of Patients for Whom Breast MRI Was Ordered and/or Scheduled | 81 | 145 | 93 | 140 |
Whether an MRI is ordered within 6 months of the mammogram date. Analyzed separately from scheduling.
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| Number of Patients for Whom Breast MRI Was Ordered | 81 | 145 | 93 | 140 |
Whether an MRI is scheduled within 6 months of the mammogram date. Analyzed separately from ordering.
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| Number of Patients Who Scheduled a Breast MRI | 56 | 94 | 54 | 87 |
Whether an MRI is completed within 6 months of the mammogram date
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| Number of Patients Who Completed a Breast MRI | 39 | 82 | 43 | 73 |
False-positive rate among those women who schedule and undergo MRI, defined as the number of patients who received a positive MRI result (i.e., BIRADS score of 4 or 5) but did not have a subsequent cancer diagnosis
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| False-positive Rate | 4 | 20 | 12 | 21 |
Cancer detection rate among those women who schedule and undergo MRI
| Participants | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge |
|---|---|---|---|---|
| Cancer Detection Rate | 3 | 3 | 0 | 0 |
Collected over Six months following the mammogram. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Usual Care (no Nudge) | 0/343 (0%) | 0/343 (0%) | 0/343 (0%) |
| Provider Nudge Only | 0/359 (0%) | 0/359 (0%) | 0/359 (0%) |
| Patient Nudge Only | 0/345 (0%) | 0/345 (0%) | 0/345 (0%) |
| Patient and Provider Nudge | 0/311 (0%) | 0/311 (0%) | 0/311 (0%) |
| Age, Continuous(years) | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge | Total |
|---|---|---|---|---|---|
| Mean | 49.68 ± 9.44 | 49.20 ± 9.19 | 48.83 ± 9.07 | 49.01 ± 9.07 | 49.18 ± 9.19 |
| Sex: Female, Male(Participants) | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge | Total |
|---|---|---|---|---|---|
| Female | 343 | 359 | 345 | 311 | 1358 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 18 | 7 | 10 | 44 |
| Not Hispanic or Latino | 332 | 339 | 330 | 299 | 1300 |
| Unknown or Not Reported | 2 | 2 | 8 | 2 | 14 |
| Race (NIH/OMB)(Participants) | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 47 | 55 | 48 | 35 | 185 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 3 | 0 | 4 |
| Black or African American | 51 | 64 | 57 | 55 | 227 |
| White | 228 | 218 | 212 | 199 | 857 |
| More than one race | 2 | 5 | 6 | 6 | 19 |
| Unknown or Not Reported | 15 | 16 | 18 | 16 | 65 |
| Region of Enrollment(participants) | Usual Care (no Nudge) | Provider Nudge Only | Patient Nudge Only | Patient and Provider Nudge | Total |
|---|---|---|---|---|---|
| United States | 343 | 359 | 345 | 311 | 1358 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Apr 2025, 18 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 18 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Abramson Cancer Center at Penn Medicine →